Home » Stocks » Cel-Sci Corporation

Cel-Sci Corporation (CVM)

Stock Price: $12.71 USD -0.34 (-2.61%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 490.91M
Revenue (ttm) 606,739
Net Income (ttm) -29.58M
Shares Out 38.62M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $12.71
Previous Close $13.05
Change ($) -0.34
Change (%) -2.61%
Day's Open 13.05
Day's Range 12.42 - 13.06
Day's Volume 287,057
52-Week Range 6.00 - 18.00

More Stats

Market Cap 490.91M
Enterprise Value 483.26M
Earnings Date (est) Dec 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.62M
Float 36.90M
EPS (basic) -0.81
EPS (diluted) -0.83
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.78M
Short Ratio 16.48
Short % of Float 26.54%
Beta 2.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 809.10
PB Ratio 26.51
Revenue 606,739
Operating Income -25.96M
Net Income -29.58M
Free Cash Flow -17.11M
Net Cash 7.65M
Net Cash / Share 0.20
Gross Margin -2,010.18%
Operating Margin -4,278.33%
Profit Margin -4,454.90%
FCF Margin -2,820.63%
ROA -46.11%
ROE -293.41%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.00*
(65.22% upside)
Low
19.0
Current: $12.71
High
23.0
Target: 21.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.540.550.070.290.660.260.160.250.960.15
Revenue Growth-2.13%693.18%-75.79%-56.64%148.98%65.45%-37.32%-73.37%523.71%-
Gross Profit0.540.550.070.290.660.260.160.250.960.15
Operating Income-20.12-16.70-21.34-23.65-32.39-25.67-19.87-17.24-17.99-18.56
Net Income-22.13-31.85-14.43-11.51-34.69-27.35-9.23-15.48-25.7110.48
Shares Outstanding31.1717.007.894.873.302.351.211.010.830.81
Earnings Per Share-0.71-1.87-1.91-2.37-10.51-12.21-16.50-19.50-37.25-15.00
Operating Cash Flow-16.32-13.39-13.79-23.08-23.83-22.93-13.55-12.19-22.56-12.80
Capital Expenditures-0.18--0.01-0.03-0.07-0.10-0.10-0.05-0.22-0.53
Free Cash Flow-16.50-13.39-13.80-23.11-23.91-23.03-13.65-12.24-22.77-13.33
Cash & Equivalents10.1211.984.044.747.7010.632.115.615.9326.59
Total Debt13.5113.3814.2113.0127.571.121.138.096.101.10
Net Cash / Debt-3.39-1.40-10.17-8.27-19.889.510.98-2.48-0.1725.49
Assets27.6229.5922.9224.8928.5519.2310.8416.0718.6337.80
Liabilities22.4929.5926.2625.5733.328.794.149.049.559.95
Book Value5.13--3.34-0.68-4.7610.446.707.039.0827.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cel-Sci Corporation
Country United States
CEO Geert R. Kersten

Stock Information

Ticker Symbol CVM
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CVM
IPO Date January 1, 1987

Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.